Engineering Fc Antibody regions to confer effector function

Details Engineering Fc Antibody regions to confer effector function Engineering Fc Antibody regions to confer effector function

2005-11-10

2009-12-15

Bristol, Lynn (Department: 1643)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Structurally-modified antibody, immunoglobulin, or fragment...

C530S388300, C530S388800

Reexamination Certificate

active

07632497

ABSTRACT:
The present invention relates to molecules having a variant Fc region, wherein said variant Fc region comprises at least one amino acid modification relative to a wild-type Fc region. These modified molecules confer an effector function to a molecule, where the parent molecule does not detectably exhibit this effector function. In particular, the molecules of the invention have an increased effector cell function mediated by a FcγR, such as, but not limited to, ADCC. In one embodiment, the variant Fc region binds FcγRIIIA and/or FcγRIIA with a greater affinity, relative to a comparable molecule comprising the wild-type Fc region. The molecules of the invention have particular utility in treatment, prevention or management of a disease or disorder, such as cancer, in a sub-population of patients, wherein the target antigen is expressed at low levels in the target cell population, in particular, in patients refractory to treatment with an existing therapeutic antibody due to the low level of target antigen expression on the cancer or associated cells.

REFERENCES:
patent: 4752601 (1988-06-01), Hahn
patent: 5348876 (1994-09-01), Michaelson et al.
patent: 5576184 (1996-11-01), Better et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5624821 (1997-04-01), Winter et al.
patent: 5648260 (1997-07-01), Winter et al.
patent: 5698449 (1997-12-01), Baumann et al.
patent: 5723584 (1998-03-01), Schatz
patent: 5736135 (1998-04-01), Goeddel et al.
patent: 5736137 (1998-04-01), Anderson et al.
patent: 5874239 (1999-02-01), Schatz
patent: 5932433 (1999-08-01), Schatz
patent: 5985599 (1999-11-01), McKenzie et al.
patent: 6025485 (2000-02-01), Kamb et al.
patent: 6114147 (2000-09-01), Frenken et al.
patent: 6165745 (2000-12-01), Ward et al.
patent: 6194551 (2001-02-01), Idusogie et al.
patent: 6210670 (2001-04-01), Berg
patent: 6242195 (2001-06-01), Idusogie et al.
patent: 6277375 (2001-08-01), Ward
patent: 6300065 (2001-10-01), Kieke et al.
patent: 6423538 (2002-07-01), Wittrup et al.
patent: 6455263 (2002-09-01), Payan
patent: 6528624 (2003-03-01), Idusogie et al.
patent: 6538124 (2003-03-01), Idusogie et al.
patent: 6737056 (2004-05-01), Presta
patent: 6821505 (2004-11-01), Ward
patent: 7315786 (2008-01-01), Dahiyat et al.
patent: 7317091 (2008-01-01), Lazar et al.
patent: 2003/0077282 (2003-04-01), Bigler et al.
patent: 2003/0158389 (2003-08-01), Idusogie et al.
patent: 2004/0002587 (2004-01-01), Watkins et al.
patent: 2004/0110226 (2004-06-01), Lazar et al.
patent: 2004/0132101 (2004-07-01), Lazar et al.
patent: 2004/0185045 (2004-09-01), Koenig et al.
patent: 2004/0220388 (2004-11-01), Mertens et al.
patent: 2005/0037000 (2005-02-01), Stavenhagen et al.
patent: 2005/0054832 (2005-03-01), Lazar et al.
patent: 2005/0064514 (2005-03-01), Stavenhagen et al.
patent: 2005/0260213 (2005-11-01), Koenig et al.
patent: 2007/0036799 (2007-02-01), Stavenhagen et al.
patent: 2008/0286819 (2008-11-01), Ravetch et al.
patent: 0 327 378 (1989-08-01), None
patent: WO 88/07089 (1988-09-01), None
patent: WO 89/07142 (1989-08-01), None
patent: WO 92/16562 (1992-10-01), None
patent: WO 93/22332 (1993-11-01), None
patent: WO 94/18330 (1994-08-01), None
patent: WO 94/29351 (1994-12-01), None
patent: WO 95/05468 (1995-02-01), None
patent: WO 97/28267 (1997-08-01), None
patent: WO 97/34631 (1997-09-01), None
patent: WO 97/44362 (1997-11-01), None
patent: WO 98/05787 (1998-02-01), None
patent: WO 98/23289 (1998-06-01), None
patent: WO 98/52975 (1998-11-01), None
patent: WO 99/43713 (1999-09-01), None
patent: WO 99/51642 (1999-10-01), None
patent: WO 99/58572 (1999-11-01), None
patent: WO 00/09560 (2000-02-01), None
patent: WO 00/42072 (2000-07-01), None
patent: WO 02/060919 (2002-08-01), None
patent: WO 02/086070 (2002-10-01), None
patent: WO 03/074679 (2003-09-01), None
patent: WO 2004/029207 (2004-04-01), None
patent: WO 2004/074455 (2004-09-01), None
patent: WO 2004/099249 (2004-11-01), None
patent: WO 2005/070963 (2005-08-01), None
patent: WO 2006/020114 (2006-02-01), None
US 6,331,391, 12/2001, Wittrup et al. (withdrawn)
ATCC search output for 2B6 hybridoma (p. 1).
Fundamental Immunology 242 (William E. Paul, M.D. ed., 3d ed. 1993).
Cavacini et al. (J. Immunol. 155:3638-3644 (1995)).
Presta (J. Allergy Clin. Immunol. 116(4):731-736 (2005).
Siberil et al. (Immunol. Letters 106:111-118 (2006).
Ibragimova and Wade (Biophysical Journal, Oct. 1999, vol. 77, pp. 2191-2198).
Jain Scientific American Jul. 1994.
Chatterjee et al Cancer Immunol. Imunother., 1994.
Dermer Biotechnology 12: 320, 1994.
Gura et al (Science vol. 278 Nov. 1997 1041-1042.
Seaver (1994; Genetic Engineering vol. 14(14):pp. 10 and 21.
Bost et al. (Immunol. Invest. (1988) 17:577-586).
Bendayan (J. Histochem. Cytochem. (1995) 43:881-886).
Altman et al., Phenotypic Analysis of Antigen-Specific T Lymphocytes, Science 274:94-96, 1996.
Angal et al., “A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody,” Mol Immunol 30 :105-108, 1993.
Armour et al., “The contrasting IgG-binding interactions of human and herpes simplex virus Fc receptors,” Biochemical Society Transactions 30:495-500, 2002.
Armour et al., “Recombinant human IgG molecules lacking Fcgamma receptor I binding and monocyte triggering activities,” Eur J Immunol 29:2613-2624, 1999.
Armour et al., “Differential binding to human FcgammaRIIa and FcgammaRIIb receptors by human IgG wildtype and mutant antibodies,” Mol Immunol 40 :585-593, 2003.
Armstrong, S. et al. “Heterogeneity of IgG1 monoclonal anti-Rh(D): an investigation using ADCC and macrophage binding assays,” Brit. J. Haematol. 66:257-262 (1987).
Baggiolini M, Dewald B. “Cellular models for the detection and evaluation of drugs that modulate human phagocyte activity,” Experientia. Oct. 15;44(10):841-848, 1988.
Boder and Wittrup, 1997, “Yeast surface display for screening combinatorial polypeptide libraries”, Nature Biotechnology 15:553-557.
Boder and Wittrup, “Optimal screening of surface-displayed polypeptide libraries,” Biotechnol Prog 14:55-62, 1998.
Boder and Wittrup, “Yeast surface display for directed evolution of protein expression, affinity, and stability,” Methods in Enzymology 328:430-444, 2000.
Boder et al., “Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity,” Proc. Natl. Acad. Sci. USA 97:10701-10705, 2000.
Bredius et al., “Role of neutrophil Fc gamma RIIa (CD32) and Fc gamma RIIIb (CD16) polymorphic forms in phagocytosis of human IgG1- and IgG3-opsonized bacteria and erythrocytes,” Immunology 83:624-630, 1994.
Brekke et al., “Human IgG isotype-specific amino acid residues affecting complement-mediated cell lysis and phagocytosis.,” Eur J Immunol 24:2542-2547, 1994.
Brown EJ., vol. 45 (Microbes as Tools for Cell Biology) inMethods In Cell Biololgy, Russell ed. Academic Press Inc. pp. 147-164, 1994.
Burlmeister et al., “Crystal structure of the complex of rat neonatal Fc receptor with Fc,” Nature 372:379-383, 1994.
Burton and Woof, “Human antibody effector function,” Advances in Immunology 51:1-84, 1992.
Burton et al., “Molecular recognition of antibody (IgG) by cellular Fc receptor (FcRI),” Mol Immunol 25:1175-1181, 1988.
Burton, “Immunoglobulin G: functional sites,” Mol Immunol 22:161-206, 1985.
Canfield and Morrison, “The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region,” J Exp Med 173:1483-1491, 1991.
Caron et al., “Engineered humanized dimeric forms of IgG are more effective antibodies,” J Exp Med 176:1191-5, 1992.
Carter et al., “Humanization of an anti-p185HER2 antibody for human cancer therapy,” Proc. Natl. Acad. Sci. USA 89:4285-4289, 1992.
Cartron et al., “Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorp

Affiliated with

Also associated with

Rating

Engineering Fc Antibody regions to confer effector function does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Engineering Fc Antibody regions to confer effector function, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Engineering Fc Antibody regions to confer effector function will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4148075